

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

DELAY IN PUBLICATION OF 2023 ANNUAL RESULTS AND SUSPENSION OF TRADING

Reference is made to (i) the announcement of Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated March 15, 2024 in relation to the board meeting of the Company for the purpose of, among other matters, considering and approving the annual results of the Group for the year ended December 31, 2023, and (ii) the announcement of the Company dated March 28, 2024 in relation to the unaudited consolidated final results of the Group for the year ended December 31, 2023.

DELAY IN PUBLICATION OF THE AUDITED 2023 ANNUAL RESULTS

The Company is unable to publish the audited annual results of the Group for the year ended December 31, 2023 (the “**2023 Annual Results**”) on March 28, 2024 in accordance with Rule 13.49(1) and 13.49(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), as the Company is still in the process of discussing with its auditors on the valuation of certain financial asset with an initial investment cost of HK\$80 million, which is pending for certain information and supporting documents.

As of the date of this announcement, the Company is proactively cooperating with its auditors to complete its auditing process as soon as possible and the Group’s business operations remain normal.

PUBLICATION OF THE 2023 UNAUDITED ANNUAL RESULTS

Pursuant to Rule 13.49(3) of the Listing Rules, if the Company is unable to publish the 2023 Annual Results within the prescribed timeframe, it must announce its results prepared based on the financial results which have yet to be agreed upon with the auditors (so far as such information is available).

In order to keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed of the business operation and financial position of the Group, the Board decided to present the unaudited consolidated final results of the Company for the year ended December 31, 2023 which have not been agreed by the Company’s auditors (the “**2023 Unaudited Annual Results**”) on March 28, 2024. At the Board meeting held on March 28, 2024, the Board reviewed and approved, among other things, the publication of the 2023 Unaudited Annual Results for the year ended December 31, 2023. The Board acknowledges that any delay in publishing the 2023 Annual Results will constitute a non-compliance with Rule 13.49(1) of the Listing Rules.

SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited will be suspended with effect from 9:00 a.m. on April 2, 2024 pending the publication of the 2023 Annual Results.

The Company will make further announcement(s) in due course to inform its Shareholders and potential investors of any information update. The Shareholders and potential investors are reminded to exercise caution when considering the 2023 Unaudited Annual Results and when dealing in the shares of the Company.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, March 28, 2024

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Dr. Zhiyun YU, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.